Understanding treatment response in pancreatic cancer: NetraAI provides genetic differentiation in FOLFIRINOX and gemcitabine response

被引：0
|
作者：
Qorri, Bessi
Tsay, Mike
Spiegel, Josh
Cook, Douglas
Geraci, Joseph
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 02期
关键词：
D O I：
10.1158/1538-7445.PANCA2023-B073
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B073
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Metastatic pancreatic cancer with complete response to FOLFIRINOX treatment
    Shelemey, Paige T.
    Amaro, Carla P.
    Ng, Danny
    Falck, Vincent
    Tam, Vincent C.
    BMJ CASE REPORTS, 2021, 14 (05)
  • [2] Predicting a Response to FOLFIRINOX in Pancreatic Cancer
    Nipp, Ryan D.
    Ryan, David P.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (08):
  • [3] Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients
    Schlick, Konstantin
    Hohla, Florian
    Hamacher, Frank
    Hackl, Hubert
    Hufnagl, Clemens
    Markus, Steiner
    Magnes, Teresa
    Gampenrieder, Simon Peter
    Melchardt, Thomas
    Staettner, Stefan
    Hauser-Kronberger, Cornelia
    Greil, Richard
    Rinnerthaler, Gabriel
    FUTURE SCIENCE OA, 2021, 7 (02):
  • [4] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
    Vaccaro, Vanja
    Sperduti, Isabella
    Milella, Michele
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (08): : 768 - 769
  • [5] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
    Conroy, Thierry
    Desseigne, Francoise
    Ychou, Marc
    Bouche, Olivier
    Guimbaud, Rosine
    Becouarn, Yves
    Adenis, Antoine
    Raoul, Jean-Luc
    Gourgou-Bourgade, Sophie
    de la Fouchardiere, Christelle
    Bennouna, Jaafar
    Bachet, Jean-Baptiste
    Khemissa-Akouz, Faiza
    Pere-Verge, Denis
    Delbaldo, Catherine
    Assenat, Eric
    Chauffert, Bruno
    Michel, Pierre
    Montoto-Grillot, Christine
    Ducreux, Michel
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19): : 1817 - 1825
  • [6] FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
    Conroy, T.
    Hammel, P.
    Hebbar, M.
    Ben Abdelghani, M.
    Wei, A. C.
    Raoul, J. -L.
    Chone, L.
    Francois, E.
    Artru, P.
    Biagi, J. J.
    Lecomte, T.
    Assenat, E.
    Faroux, R.
    Ychou, M.
    Volet, J.
    Sauvanet, A.
    Breysacher, G.
    Di Fiore, F.
    Cripps, C.
    Kavan, P.
    Texereau, P.
    Bouhier-Leporrier, K.
    Khemissa-Akouz, F.
    Legoux, J. -L.
    Juzyna, B.
    Gourgou, S.
    O'Callaghan, C. J.
    Jouffroy-Zeller, C.
    Rat, P.
    Malka, D.
    Castan, F.
    Bachet, J. -B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25): : 2395 - 2406
  • [7] Biomarkers of Gemcitabine Response in Pancreatic Cancer
    Chang, D. K.
    Colvin, E. K.
    Scarlett, C. J.
    Pinese, M.
    Goldstein, D.
    Merrett, N. D.
    Musgrove, E. A.
    Henshall, S. M.
    Sutherland, R. L.
    Kench, J. G.
    Biankin, A. V.
    PANCREAS, 2009, 38 (08) : 987 - 988
  • [8] Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pancreatic Cancer
    Luu, Andreas Minh
    Hoehn, Philipp
    Vogel, SinaRabea
    Reinacher-Schick, Anke
    Munding, Johanna
    Uhl, Waldemar
    Braumann, Chris
    VISCERAL MEDICINE, 2019, 35 (06) : 387 - 390
  • [9] FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer
    Luu, Andreas Minh
    Herzog, Torsten
    Hoehn, Philipp
    Reinacher-Schick, Anke
    Munding, Johanna
    Uhl, Waldemar
    Braumann, Chris
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 9 (02) : E9 - E12
  • [10] ECONOMIC EVALUATION OF FOLFIRINOX VERSUS GEMCITABINE IN THE TREATMENT OF METASTATIC PANCREATIC CANCER IN JAPAN
    Hirota, Y.
    Nishiuchi, Y.
    Ueda, M.
    Moriwaki, K.
    VALUE IN HEALTH, 2019, 22 : S74 - S75
12345